Selected research
Industry Research
Long-acting Melatonin Receptor Agonists Industry Research Report 2026
Market perspective
The global Long-acting Melatonin Receptor Agonists market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Long-acting Melatonin Receptor Agonists market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Long-acting Melatonin Receptor Agonists market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Long-acting Melatonin Receptor Agonists market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Long-acting Melatonin Receptor Agonists include Takeda, Sichuan Kelun Pharmaceuticals, Sichuan Guowei Pharmaceuticals, Novartis, Jiangsu Hausen Pharmaceuticals, Hangzhou Lingye Pharmaceutical Technology, Guangdong Annuo Pharmaceuticals, Vanda Pharmaceuticals and Servier Laboratories, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Long-acting Melatonin Receptor Agonists market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Long-acting Melatonin Receptor Agonists.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Long-acting Melatonin Receptor Agonists Market by Company
Takeda
Sichuan Kelun Pharmaceuticals
Sichuan Guowei Pharmaceuticals
Novartis
Jiangsu Hausen Pharmaceuticals
Hangzhou Lingye Pharmaceutical Technology
Guangdong Annuo Pharmaceuticals
Vanda Pharmaceuticals
Servier Laboratories
Rovi Pharma
Nectid Inc
Dr Reddy's Laboratories
Long-acting Melatonin Receptor Agonists Segment by Type
Ramelteon
Agomelatine
Other
Long-acting Melatonin Receptor Agonists Segment by Application
Hospital
Clinic
Other
Long-acting Melatonin Receptor Agonists Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Melatonin Receptor Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Long-acting Melatonin Receptor Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Melatonin Receptor Agonists.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Long-acting Melatonin Receptor Agonists companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ramelteon
- Agomelatine
- Other
Applications
- Hospital
- Clinic
- Other
Companies covered
- Takeda
- Sichuan Kelun Pharmaceuticals
- Sichuan Guowei Pharmaceuticals
- Novartis
- Jiangsu Hausen Pharmaceuticals
- Hangzhou Lingye Pharmaceutical Technology
- Guangdong Annuo Pharmaceuticals
- Vanda Pharmaceuticals
- Servier Laboratories
- Rovi Pharma
- Nectid Inc
- Dr Reddy's Laboratories
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Long-acting Melatonin Receptor Agonists by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Ramelteon
- 2.2.3 Agomelatine
- 2.2.4 Other
- 2.3 Long-acting Melatonin Receptor Agonists by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Long-acting Melatonin Receptor Agonists Breakdown Data by Type
- 3.1 Global Long-acting Melatonin Receptor Agonists Historic Market Size by Type (2021-2026)
- 3.2 Global Long-acting Melatonin Receptor Agonists Forecasted Market Size by Type (2027-2032)
4 Long-acting Melatonin Receptor Agonists Breakdown Data by Application
- 4.1 Global Long-acting Melatonin Receptor Agonists Historic Market Size by Application (2021-2026)
- 4.2 Global Long-acting Melatonin Receptor Agonists Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Long-acting Melatonin Receptor Agonists Market Perspective (2021-2032)
- 5.2 Global Long-acting Melatonin Receptor Agonists Growth Trends by Region
- 5.2.1 Global Long-acting Melatonin Receptor Agonists Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Long-acting Melatonin Receptor Agonists Historic Market Size by Region (2021-2026)
- 5.2.3 Long-acting Melatonin Receptor Agonists Forecasted Market Size by Region (2027-2032)
- 5.3 Long-acting Melatonin Receptor Agonists Market Dynamics
- 5.3.1 Long-acting Melatonin Receptor Agonists Industry Trends
- 5.3.2 Long-acting Melatonin Receptor Agonists Market Drivers
- 5.3.3 Long-acting Melatonin Receptor Agonists Market Challenges
- 5.3.4 Long-acting Melatonin Receptor Agonists Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Long-acting Melatonin Receptor Agonists Players by Revenue
- 6.1.1 Global Top Long-acting Melatonin Receptor Agonists Players by Revenue (2021-2026)
- 6.1.2 Global Long-acting Melatonin Receptor Agonists Revenue Market Share by Players (2021-2026)
- 6.2 Global Long-acting Melatonin Receptor Agonists Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Long-acting Melatonin Receptor Agonists Head Office and Area Served
- 6.4 Global Long-acting Melatonin Receptor Agonists Players, Product Type & Application
- 6.5 Global Long-acting Melatonin Receptor Agonists Manufacturers Established Date
- 6.6 Global Long-acting Melatonin Receptor Agonists Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Long-acting Melatonin Receptor Agonists Market Size (2021-2032)
- 7.2 North America Long-acting Melatonin Receptor Agonists Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Long-acting Melatonin Receptor Agonists Market Size by Country (2021-2026)
- 7.4 North America Long-acting Melatonin Receptor Agonists Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Long-acting Melatonin Receptor Agonists Market Size (2021-2032)
- 8.2 Europe Long-acting Melatonin Receptor Agonists Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Long-acting Melatonin Receptor Agonists Market Size by Country (2021-2026)
- 8.4 Europe Long-acting Melatonin Receptor Agonists Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Long-acting Melatonin Receptor Agonists Market Size (2021-2032)
- 9.2 Asia-Pacific Long-acting Melatonin Receptor Agonists Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Long-acting Melatonin Receptor Agonists Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Long-acting Melatonin Receptor Agonists Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Long-acting Melatonin Receptor Agonists Market Size (2021-2032)
- 10.2 South America Long-acting Melatonin Receptor Agonists Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Long-acting Melatonin Receptor Agonists Market Size by Country (2021-2026)
- 10.4 South America Long-acting Melatonin Receptor Agonists Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Long-acting Melatonin Receptor Agonists Market Size (2021-2032)
- 11.2 Middle East & Africa Long-acting Melatonin Receptor Agonists Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Long-acting Melatonin Receptor Agonists Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Long-acting Melatonin Receptor Agonists Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda
- 12.1.1 Takeda Company Information
- 12.1.2 Takeda Business Overview
- 12.1.3 Takeda Revenue in Long-acting Melatonin Receptor Agonists Business (2021-2026)
- 12.1.4 Takeda Long-acting Melatonin Receptor Agonists Product Portfolio
- 12.1.5 Takeda Recent Developments
- 12.2 Sichuan Kelun Pharmaceuticals
- 12.2.1 Sichuan Kelun Pharmaceuticals Company Information
- 12.2.2 Sichuan Kelun Pharmaceuticals Business Overview
- 12.2.3 Sichuan Kelun Pharmaceuticals Revenue in Long-acting Melatonin Receptor Agonists Business (2021-2026)
- 12.2.4 Sichuan Kelun Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio
- 12.2.5 Sichuan Kelun Pharmaceuticals Recent Developments
- 12.3 Sichuan Guowei Pharmaceuticals
- 12.3.1 Sichuan Guowei Pharmaceuticals Company Information
- 12.3.2 Sichuan Guowei Pharmaceuticals Business Overview
- 12.3.3 Sichuan Guowei Pharmaceuticals Revenue in Long-acting Melatonin Receptor Agonists Business (2021-2026)
- 12.3.4 Sichuan Guowei Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio
- 12.3.5 Sichuan Guowei Pharmaceuticals Recent Developments
- 12.4 Novartis
- 12.4.1 Novartis Company Information
- 12.4.2 Novartis Business Overview
- 12.4.3 Novartis Revenue in Long-acting Melatonin Receptor Agonists Business (2021-2026)
- 12.4.4 Novartis Long-acting Melatonin Receptor Agonists Product Portfolio
- 12.4.5 Novartis Recent Developments
- 12.5 Jiangsu Hausen Pharmaceuticals
- 12.5.1 Jiangsu Hausen Pharmaceuticals Company Information
- 12.5.2 Jiangsu Hausen Pharmaceuticals Business Overview
- 12.5.3 Jiangsu Hausen Pharmaceuticals Revenue in Long-acting Melatonin Receptor Agonists Business (2021-2026)
- 12.5.4 Jiangsu Hausen Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio
- 12.5.5 Jiangsu Hausen Pharmaceuticals Recent Developments
- 12.6 Hangzhou Lingye Pharmaceutical Technology
- 12.6.1 Hangzhou Lingye Pharmaceutical Technology Company Information
- 12.6.2 Hangzhou Lingye Pharmaceutical Technology Business Overview
- 12.6.3 Hangzhou Lingye Pharmaceutical Technology Revenue in Long-acting Melatonin Receptor Agonists Business (2021-2026)
- 12.6.4 Hangzhou Lingye Pharmaceutical Technology Long-acting Melatonin Receptor Agonists Product Portfolio
- 12.6.5 Hangzhou Lingye Pharmaceutical Technology Recent Developments
- 12.7 Guangdong Annuo Pharmaceuticals
- 12.7.1 Guangdong Annuo Pharmaceuticals Company Information
- 12.7.2 Guangdong Annuo Pharmaceuticals Business Overview
- 12.7.3 Guangdong Annuo Pharmaceuticals Revenue in Long-acting Melatonin Receptor Agonists Business (2021-2026)
- 12.7.4 Guangdong Annuo Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio
- 12.7.5 Guangdong Annuo Pharmaceuticals Recent Developments
- 12.8 Vanda Pharmaceuticals
- 12.8.1 Vanda Pharmaceuticals Company Information
- 12.8.2 Vanda Pharmaceuticals Business Overview
- 12.8.3 Vanda Pharmaceuticals Revenue in Long-acting Melatonin Receptor Agonists Business (2021-2026)
- 12.8.4 Vanda Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio
- 12.8.5 Vanda Pharmaceuticals Recent Developments
- 12.9 Servier Laboratories
- 12.9.1 Servier Laboratories Company Information
- 12.9.2 Servier Laboratories Business Overview
- 12.9.3 Servier Laboratories Revenue in Long-acting Melatonin Receptor Agonists Business (2021-2026)
- 12.9.4 Servier Laboratories Long-acting Melatonin Receptor Agonists Product Portfolio
- 12.9.5 Servier Laboratories Recent Developments
- 12.10 Rovi Pharma
- 12.10.1 Rovi Pharma Company Information
- 12.10.2 Rovi Pharma Business Overview
- 12.10.3 Rovi Pharma Revenue in Long-acting Melatonin Receptor Agonists Business (2021-2026)
- 12.10.4 Rovi Pharma Long-acting Melatonin Receptor Agonists Product Portfolio
- 12.10.5 Rovi Pharma Recent Developments
- 12.11 Nectid Inc
- 12.11.1 Nectid Inc Company Information
- 12.11.2 Nectid Inc Business Overview
- 12.11.3 Nectid Inc Revenue in Long-acting Melatonin Receptor Agonists Business (2021-2026)
- 12.11.4 Nectid Inc Long-acting Melatonin Receptor Agonists Product Portfolio
- 12.11.5 Nectid Inc Recent Developments
- 12.12 Dr Reddy's Laboratories
- 12.12.1 Dr Reddy's Laboratories Company Information
- 12.12.2 Dr Reddy's Laboratories Business Overview
- 12.12.3 Dr Reddy's Laboratories Revenue in Long-acting Melatonin Receptor Agonists Business (2021-2026)
- 12.12.4 Dr Reddy's Laboratories Long-acting Melatonin Receptor Agonists Product Portfolio
- 12.12.5 Dr Reddy's Laboratories Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst